CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland.  Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, please visit www.cnspharma.com.

CNS Pharmaceuticals, Inc.

Happy Thanksgiving from all of us at CNS Pharmaceuticals! We hope you enjoy a day of good company and good food.

Florida Girl, 8, Girl, Spends Holiday In DC For Rare Brain Cancer Treatment  https://ibn.fm/7js7F

Industry News:    Brain Cancer Thrives By Hijacking Mechanisms To Boost Synapse Strength  https://ibn.fm/dTSps     #braincancer  #glioblastoma #neuro-oncology

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

https://bit.ly/3MW5gmv 
#GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

Industry News:   Finger-prick Test Could Help Spot Brain Cancer Recurrence Sooner  https://ibn.fm/H3BYY    #braincancer  #glioblastoma #neuro-oncology

Meet our dedicated, experienced team here: https://bit.ly/3tCAjx9 

#GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

Industry News:    Actor Had Brain Tumor The Size Of A Lime  https://ibn.fm/gEjkC    #braincancer  #glioblastoma #neuro-oncology

Watch this video on how our lead product candidate, Berubicin is designed to work: https://bit.ly/3ZWWubF  

#GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

https://bit.ly/46fHoB9 
 #GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

Industry News:   Lung Cancer Cells Covertly Thrive In Brain Under Guise Of Protection, Stanford Medicine Study Finds  https://ibn.fm/zAqz9   #braincancer  #glioblastoma #neuro-oncology

DNSSEC

Amazon

AWS Global Accelerator

Amazon Frankfurt Region

BunnyCDN Header

Craft

Chairman and Chief Executive Officer

John Climaco

Jeff Keyes

Bettina Cockroft

Founder, Chairman and Chief Executive Officer

Pharmaceutical Companies (Top 10K)

Houston Companies With Fewer Than 50 Employees (Top 10K)

Southern US Pharmaceutical Companies

Therapeutics Companies that Exited

CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. CNS may also pursue the development of Berubicin to treat additional diseases, including pancreatic and ovarian cancers and lymphoma. CNS may also develop combination therapies that include Berubicin.

Post-IPO Equity - CNS Pharmaceutical

Houston

Texas

United States

North America

CNS Pharmaceutical

CNS Pharmaceuticals Announces Abstract Accepted for Poste...

CNS Pharmaceuticals Reports Third Quarter 2024 Financial...

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceutical files for 2.36M offering of common stock

CNS Pharmaceuticals prices registered direct offering, private placement

Central Nervous System (CNS) Stimulant Drugs Market size is set to grow by USD 6.48 billion from 2023-2027, Rise in ...

CNS Biomarkers Expected to Grow at CAGR of 7.67% over the forecast period

An anthracycline-based chemotherapy drug designed to cross the blood-brain barrier for the treatment of glioblastoma multiforme.

A drug technology utilizing anthracycline and distamycin-based scaffolds aimed at treating brain and central nervous system cancers, with preclinical studies showing high brain uptake and antitumor activity.

A program that may provide physicians with CNS Pharmaceuticals' investigational drugs for treating patients with serious or life-threatening conditions outside of clinical trials under certain criteria.

Israel

Asia

South Korea

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	66a93f32
crunchbase profile	general	Nov 27, 2024 1:01 PM	849e27fe
li profile	general	Jan 30, 2024 6:39 AM	171f95d9
translate crunchbase fundingrounds	general	Nov 27, 2024 2:59 PM	1410a6e4
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CNSPHARMA

CNS Pharmaceuticals, Inc.

Last Close

0.13

22/11 21:00

Market Cap

1.52M

Beta: -

Volume Today

194.47K

Avg: -